Move the reimbursement sliders by region and choose an Alpha DaRT capture rate to see the total addressable market, in billions, today (2026) and projected to 2050.
Alpha Tau Medical · DRTS · Draft v1
Global TAM · 2026
$0B
→ 2050
Modelling assumption: this tool assumes full regulatory approval (FDA, EMA, PMDA and equivalents) across all geographies and all solid tumours, alone or in combination with checkpoint inhibitors. It is a TAM ceiling — every appropriate patient treated once in a single year — not a revenue forecast. No adoption ramp, competition, or probability of success is applied.
TAM · 2026 (today)
$0B
TAM · 2050 (projected)
$0B
Alpha DaRT treatable cases · 2026
0/yr
1 · Alpha DaRT capture of solid tumours
Share of solid-tumour cases Alpha DaRT captures each year. 10% is the baseline case.
2 · Reimbursement by region ($ / treated patient)
Click a region to set prices. Differentiated markets price brain / pancreas / other separately.
From cancer cases to addressable market
2026 · today
2050 · projected
Brain / CNSPancreaticAll other solid
TAM by region
2026bar length scaled to the largest region · 2050 shown as outline